

EVALUATION FORM

ASSOCIATION OF MEDICAL LABORATORY IMMUNOLOGISTS (AMLI) 33rd VIRTUAL ANNUAL MEETING *August 2020*

Please evaluate the following speakers and subjects on the basis of Excellent = 4; Very Good = 3; Good = 2; Fair = 1; and Poor = 0. Please circle the number you feel applies. These evaluations will provide the course directors with a summary to aid in planning future programs.

Please return the completed Evaluation Form to the Registration Desk before you leave. Your name, while not mandatory, is requested in order to allow outcomes follow up. Your evaluations will be kept confidential.

Your Name (please print)

PLENARY SESSION 1 Monday, August 3 and Tuesday, August 4 HISTOCOMPATIBILITY TESTING AND TRANSPLANT IMMUNOLOGY Chairs: Medhat Askar, M.D. and Evan Ntrivalas, M.D., Ph.D.

A Coming of Age of Immunogenetics Testing in Transplantation and Cellular Therapy Medhat Askar, M.D., Baylor University Medical Center

Objectives: At the end of the session the participants should be able to 1) assess actionable testing in pre-transplant evaluation transplantation and cellular therapy (TCT) recipients and donors; 2) assess actionable testing in post-transplant monitoring of transplantation and cellular therapy (TCT) recipients and donors; and 3) interpret results of pre-transplant evaluation and post-transplant monitoring of transplantation and cellular therapy (TCT) recipients and donors testing results.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?			yes	no	
			yes	no	
			yes	no	

Milestones of Immune Reconstitution that are Predictable and Modifiable are Associated with Improved Transplant Outcomes

Susan Prockop, M.D., Memorial Sloan Kettering Cancer Center

Objectives: At the end of the session the participants should be able to: 1) review the milestones of post HCT T cell immune reconstitution that have been associated with important outcomes; 2) determine how pre-transplant events and elements of the conditioning regimen can predict whether patients achieve these milestones; and 3) recognize which of the predictors of immune reconstitution are modifiable and the efforts currently in place to attempt predictable early T cell immune reconstitution.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Flow Cytometric Assays for Monitoring of Immune Cell Reconstitution after Hematopoietic Stem Cell Transplantation

Evan Ntrivalas, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

Objectives: At the end of the session the participants should be able to 1) identify the timing of immune cell engraftment after hematopoietic stem cell transplantation (HSCT); 2) discuss the role of flow cytometry in monitoring immune cell reconstitution after HSCT; and 3) discuss the phenotypic and functional flow cytometric assays used in patients with hematological malignancies.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients

Swati Naik, MBBS, Texas Children's Cancer Center, Baylor College of Medicine

Objectives: At the end of the session the participants should be able to 1) evaluate the effects of conditioning on immune recovery after hematopoietic stem cell transplantation (HSCT); 2) describe the most common infections associated with post-HSCT clinical outcomes; and 3) outline the clinical use of functional monitoring assays in assisting clinical care and personalized management of HSCT recipients with infections.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

PLENARY SESSION 2

Tuesday, August 11 and Wednesday, August 12

CASE STUDIES

Chair: Eric Weimer

Acquired Immune Defects and Chronic Infections – Laboratory Investigations

Vijaya Knight, M.D., Ph.D., (D)ABMLI, University of Colorado School of Medicine and Children's Hospital, Colorado

Objectives: At the end of the session the participants should be able to: 1) enumerate diseases associated with anti-cytokine antibodies; 2) describe laboratory techniques to detect anti-cytokine antibodies; and 3) enumerate reasons to consider anti-cytokine antibodies in the differential diagnosis of chronic infections.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

A Case of COVID-19? To be Determined by Serology ...

Caleb Cornaby, Ph.D., MB(ASCP)^{cm}, UNC Health

Objectives: At the end of the session the participants should be able to: 1) recall common clinical symptoms associated with SARS-Cov-2 infection; 2) relate how SARS-Cov-2 serology can be clinically useful in cases suspicious for COVID-19; and 3) recognize when it would be useful to recommend serological testing for SARS-Cov-2.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

A Case of Aberrant CD8 T Cell-restricted IL-7 Signaling with a Janus Kinase 3 Defect-associated Atypical Severe Combined Immunodeficiency

Aaruni Khanolkar, MBBS, Ph.D., D(ABMLI), Feinberg School of Medicine at Northwestern University

Objectives: At the end of the session the participants should be able to: 1) identify the difference between typical and atypical JAK3-associated SCID; 2) recognize the need to perform in depth phenotyping of immune cell subsets as well as interrogate functional properties of immune cells to resolve unusual immunological observations; 3) recognize the importance of a fine-tuned, interdisciplinary effort between the immunology clinic, the immunology-laboratory and the genomics-laboratory in coordinating the effective management of patients with complex immunological disorders.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

An Interesting Case of ... COVID-19?

Matthew Sims, M.D., P.D., FACP, FIDSA, Beaumont Research Institute

Objectives: At the end of the session the participants should be able to: 1) describe the use of various tests in the workup of a person under investigation for COVID-19.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	

NETER AWARD RECIPIENT LECTURE
Tuesday, August 11

AMLI and Clinical Laboratory Immunology from AIDS in the 1980s to SARS-Co-V-2 in the 2020s

Thomas S. Alexander, Ph.D., D(ABMLI), FlowMetric Diagnostics and Summit Pathology

Objectives: At the end of the session the participants should be able to 1) describe the influence of HIV infection on clinical immunology labs; 2) describe the effect of increased autoantibody detection over the past decades on the growth of AMLI and clinical laboratory immunology; 3) discuss the rise, fall and potential resurrection of immunology certification exams at both the technologist and doctoral levels; and 4) determine how the newfound public interest in serology testing facilitated by the SARS-Co-V-2 pandemic may affect clinical laboratory immunology.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	
	4.		yes	no	

PLENARY SESSION 3

Sunday, August 16 and Monday, August 17

SECONDARY IMMUNODEFICIENCY AND IMMUNOTHERAPY MONITORING

Chairs: Amir A. Sadighi Akha, Sara Nandiwada and Vijaya Knight

Nurture Overwhelming Nature: An Overview of Secondary Immunodeficiency States

Cullen M. Dutmer, M.D., University of Colorado School of Medicine and Children’s Hospital Colorado

Objectives: At the end of the session the participants should be able to 1) describe clinical phenotypes that will result from disruption of specific compartments of the immune system; 2) list common etiologies of secondary immunodeficiency states; and 3) describe features that may distinguish secondary from primary immunodeficiency states.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Secondary Immunodeficiency Due to Malignancy

Sameer A. Parikh, MBBS, Mayo Clinic

Objectives: At the end of the session the participants should be able to 1) recognize the type and extent of immunodeficiency in patients with previously untreated hematologic malignancies, including precursor non-malignant conditions; 2) describe the clinical impact of immunodeficiency in patients with untreated hematologic malignancies.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	

Immunodeficiency Secondary to Infectious Diseases

Thomas G. Boyce, M.D., MPH, Marshfield Clinic

Objectives: At the end of the session the participants should be able to 1) name the infections most commonly associated with secondary immune deficiency; 2) describe the mechanism by which HIV infection escapes the immune system; and 3) list the tests that should be done to assess immune function in a patient suspected of having immune deficiency secondary to infection.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Consequences of Therapeutic Immune Suppression: Recognition and Monitoring

Tiphonie P. Vogel, M.D., Ph.D., Texas Children's Hospital

Objectives: At the end of the session the participants should be able to 1) recall at least two ways corticosteroids can impact assessments of immune function; 2) recognize at least three specialty immune phenotyping studies that can be altered by biologic therapies; and 3) identify at least four common rheumatologic medications that require regular monitoring of complete blood counts.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

PLENARY SESSION 4, Part 1
Saturday, August 22
ANA UPDATE

Chairs: Kamran Kadkhoda, Lisa Peterson and Anne Tebo

The International Consensus on ANA Patterns (ICAP): a 2020 Update

Edward K. L. Chan, Ph.D., University of Florida

Objectives: At the end of the session the participants should be able to 1) describe the aims and scope of ICAP; 2) determine the most appropriate use of the www.ANAPatterns.org website including pattern identification and clinical relevance; and 3) describe current and future ICAP initiatives.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Patterns, Titers, and Cytoplasmics, Oh My: Results of the AMLI Survey on Interpretation & Reporting of HEp-2 Antinuclear Antibody Tests

Mark T. Wener, M.D., University of Washington

Objectives: At the end of the session the participants should be able to 1) describe differences in the reporting of ANA patterns; 2) identify difficult to interpret ANA patterns; and 3) discuss the significance of survey results in promoting harmonization.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

PLENARY SESSION 4, Part 2
Sunday, August 23
ANTIBODY TESTING FOR COVID-19
Chairs: John Schmitz and Stanley Naides

Emergence of Antibody Testing During the COVID-19 Pandemic

Gabriel Maine, Ph.D., Beaumont Health

Objectives: At the end of the session the participants should be able to 1) provide an overview of the emergence of antibody testing and the challenges that were encountered during the early stages of the pandemic in the U.S.; 2) describe clinical utility and test performance characteristics of two commercial COVID-19 antibody assays; and 3) explain what we have learned from COVID-19 serology testing.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?			yes	no	
			yes	no	
			yes	no	

The Design and Execution of a Health System Wide Seroprevalence Study for COVID-19

Matthew Sims, M.D., Ph.D., FACP, FIDSA, Beaumont Research Institute

Objectives: At the end of the session the participants should be able to 1) describe the rationale of a health system wide seroprevalence study during a pandemic; and 2) review the challenges in developing and executing such a study.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?			yes	no	
			yes	no	

PLENARY SESSION 5
Sunday, August 30 and Monday, August 31
EMERGING INFECTIOUS DISEASES AND NEW ALGORITHMS FOR TESTING HIV,
LYME, ETC.

Chairs: Stanley Naides and Melissa Snyder

Modified Two-tiered Serological Testing for Lyme Disease

William Lee, Ph.D., New York State Department of Health

Objectives: At the end of the session the participants should be able to 1) recognize new modified testing algorithm for Lyme Disease serology; 2) identify pros and cons of the new algorithm; and 3) discover if using the modified two-tier approach is appropriate for their own Lyme Disease serology testing.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Tick-borne Infections – Beyond Lyme Disease

Elitza S. Theel, Ph.D., D(ABMM), Mayo Clinic

Objectives: At the end of the session the participants should be able to 1) identify the common tick-borne infections in North America, beyond just Lyme disease; 2) describe key clinical features of non-Lyme disease tick-borne infections; and 3) discuss recommended diagnostic testing approaches for tick-borne diseases.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
<hr/>					
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Emerging Arbovirus Disease: Chikungunya, Mayaro Virus and Oropouche Virus, and Powassan Virus

Aileen Chang, M.D., MSPH, George Washington University

Objectives: At the end of the session the participants should be able to 1) describe the clinical presentation of Chikungunya, Mayaro, Oropouche, and Powassan Virus; 2) describe the locations where these viruses are endemic; and 3) describe the mode of transmission of each of the viruses.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	

Epidemiology and Diagnostic Capacity for U.S. Domestic Arboviruses: Role of Classical and Next Generation Technologies

Aaron C. Brault, Ph.D., US Centers for Disease Control and Prevention

Objectives: At the end of the session the participants should be able to 1) identify the epidemiology of principal and emerging domestic arboviral agents in the United States; 2) describe diagnostic testing available for domestic arboviruses; 3) interpret diagnostic testing results for arboviruses; and 4) explain enhanced testing available by CDC through coordination with state health departments during COVID pandemic.

	Excellent	Very Good	Good	Fair	Poor
A. Overall value to you	4	3	2	1	0
B. Educational objectives were clear	4	3	2	1	0
C. Speaker was effective	4	3	2	1	0
D. A-V aids were effective	4	3	2	1	0
E. I am likely to make a change(s) based on this presentation: List change(s) _____		yes	no		
F. Were the objectives met?	1.		yes	no	
	2.		yes	no	
	3.		yes	no	
	4.		yes	no	

OUTCOME ASSESSMENT

Rate your ability in the following before AND after this program:
(1=low; 2=moderately low; 3=moderate; 4=moderately high; 5=high)

	Before	After
1. My understanding of A Coming of Age of Immunogenetics Testing in Transplantation and Cellular Therapy		
2. My understanding of Milestones of Immune Reconstitution that are Predictable and Modifiable are Associated with Improved Transplant Outcomes		
3. My understanding of Flow Cytometric Assays for Monitoring of Immune Cell Reconstitution after Hematopoietic Stem Cell Transplantation		
4. My understanding of Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients		
5. My understanding of Acquired Immune Defects and Chronic Infections – Laboratory Investigations		
6. My understanding of The Application and Utility of a Primary Immunodeficiency Diagnosis Tool A Case of COVID-19? To be Determined by Serology ...		
7. My understanding of A Case of Aberrant CD8 T Cell-restricted IL-7 Signaling with a Janus Kinase 3 Defect-associated Atypical Severe Combined Immunodeficiency		
8. My understanding of An Interesting Case of ... COVID-19?		
9. My understanding of AMLI and Clinical Laboratory Immunology from AIDS in the 1980s to SARS-Co-V-2 in the 2020s		
10. My understanding of Nurture Overwhelming Nature: An Overview of Secondary Immunodeficiency States		
11. My understanding of Secondary Immunodeficiency Due to Malignancy		
12. My understanding of Immunodeficiency Secondary to Infectious Diseases		
13. My understanding of Consequences of Therapeutic Immune Suppression: Recognition and Monitoring		
14. My understanding of Systemic Lupus Erythematosus in a Child with Ulcerative Colitis The International Consensus on ANA Patterns (ICAP): a 2020 Update		
15. My understanding of Interpretation and Reporting of Antinuclear Antibodies: Results from a Recent AMLI Performance Survey		
16. My understanding of Emergence of Antibody Testing During the COVID-19 Pandemic The Design and Execution of a Health System Wide Seroprevalence Study for COVID-19		
17. My understanding of Modified Two-tiered Serological Testing for Lyme Disease		
18. My understanding of Tick-borne Infections – Beyond Lyme Disease		
19. My understanding of Emerging Arbovirus Disease: Chikungunya, Mayaro Virus and Oropouche Virus, and Powassan Virus		
20. My understanding of An Update on Endemic Mosquito-Borne Viruses in the U.S.		

Indicate your agreement with the following:

	Strongly Agree 4	Agree 3	Strongly Disagree 2	Disagree 1
21. The pace of the program was satisfactory: If the pace was unsatisfactory, was it (circle one): too fast or too slow				
22. The content was useful.				
23. The materials were useful.				
24. The instructional methods were effective.				
25. The Virtual Meeting was adequate for your needs.				

SUGGESTIONS

Topics for Future Meetings:

Program Format Changes:

Future Meeting Location(s):